Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
Authors
Keywords
-
Journal
Blood Advances
Volume 5, Issue 13, Pages 2775-2787
Publisher
American Society of Hematology
Online
2021-07-12
DOI
10.1182/bloodadvances.2021004233
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial
- (2020) Andrew Henry Wei et al. BLOOD
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- How I treat acute myeloid leukemia in the era of new drugs
- (2019) Courtney D. DiNardo et al. BLOOD
- How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
- (2019) Brian A. Jonas et al. LEUKEMIA
- Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?
- (2019) Benjamin A. Derman et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia
- (2017) A-K Eisfeld et al. LEUKEMIA
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Venetoclax: First Global Approval
- (2016) Emma D. Deeks DRUGS
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- How I treat the older patient with acute myeloid leukemia
- (2014) G. Ossenkoppele et al. BLOOD
- Antisense Oligonucleotide Therapies
- (2014) Kendall S. Frazier TOXICOLOGIC PATHOLOGY
- BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
- (2013) Eleni D. Lagadinou et al. Cell Stem Cell
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
- (2013) R. Pan et al. Cancer Discovery
- Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia
- (2012) Krzysztof Mrózek et al. JOURNAL OF CLINICAL ONCOLOGY
- Central roles of apoptotic proteins in mitochondrial function
- (2012) S M Kilbride et al. ONCOGENE
- Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With,CEBPAMutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study
- (2008) Guido Marcucci et al. JOURNAL OF CLINICAL ONCOLOGY
- The BCL-2 protein family: opposing activities that mediate cell death
- (2007) Richard J. Youle et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started